How Much Value is Your Company Losing? Implementing Effective Intellectual Property Management

Gunnar Wieboldt, Senior Corporate Counsel, Talecris Biotherapeutics, USA

Increasingly most of the value of a company today can be attributed to its intellectual property and other intangible assets. Without effective management of these assets, including governance committees, intellectual property audits, invention disclosure processes, and trade secret registries, much of this value can be overlooked, poorly leveraged, or even lost. Implementation of effective intellectual property management is not only good business, but increasingly a requirement for accurate financial reporting and compliance. 1. Introduction Three years ago I was hired as in-house counsel responsible for intellectual property for a recently spun-off division of Bayer Healthcare. The new company, Talecris Biotherapeutics, was respectably large and established with over 2,000 employees and one billion dollars (USD) worth of world-wide biopharmaceutical sales. However, in many respects it was a start-up forced to create from scratch functions historically handled by its former parent company. This deficiency was most notably true with respect to intellectual property management. I became aware of our lack of intellectual property infrastructure when, soon after joining Talecris, I was handed a list of twenty patents whose maintenance fees were coming due and asked 'which were worth the expense?' That an attorney alone would be given this task underscored the need to make some changes. What followed from this request was a series of initiatives that have greatly increased awareness of intellectual property throughout the organization (including a 300% increase in invention disclosures), improved the decision making surrounding intellectual property resources and assets, and made it easier for the chief financial officer and the chief executive to stand by their public disclosures of company value.

Read full paper Subscribe to the IICJ
USA Intellectual Property Pharmaceutical March 2008 Vol. 1, No. 3, Spring 2008

Gunnar Wieboldt

More

BA Univ. of Rochester 1992 - USMC Major 1992-1998 - JD Harvard Law 1999 - Corporate Counsel, Life Sciences practice, Hill and Barlow, PC in Boston 2001-2003 - Associate, IP Litigation, Robins Kaplan LLP in Minneapolis 2003-2004 - Senior Corporate Counsel, IP

Talecris Biotherapeutics

More

Talecris Biotherapeutics is a 1.2 Billion dollar revenue plasma derived protein therapeutics company that sells its products worldwide with operations in the US, Canada and Germany

USA Intellectual Property Pharmaceutical March 2008 Vol. 1, No. 3, Spring 2008